Stock Scorecard
Stock Summary for Cassava Sciences Inc (SAVA) - $27.08 as of 10/4/2024 9:27:46 PM EST
Total Score
11 out of 30
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for SAVA
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for SAVA
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for SAVA
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 | |
Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for SAVA
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for SAVA
Financial Details for SAVA
Company Overview |
|
---|---|
Ticker | SAVA |
Company Name | Cassava Sciences Inc |
Country | USA |
Description | Cassava Sciences, Inc., a clinical-stage biotechnology company, develops drugs for neurodegenerative diseases. The company is headquartered in Austin, Texas. |
Sector Name | LIFE SCIENCES |
Industry Name | PHARMACEUTICAL PREPARATIONS |
Most Recent Quarter | 6/30/2024 |
Next Earnings Date | 11/5/2024 |
Stock Price History |
|
Last Day Price | 27.08 |
Last Day Price Updated | 10/4/2024 9:27:46 PM EST |
Last Day Volume | 790,109 |
Average Daily Volume | 1,652,689 |
52-Week High | 42.20 |
52-Week Low | 8.79 |
Last Price to 52 Week Low | 208.08% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 35.61 |
Sector PE | 81.40 |
5-Year Average PE | -13.01 |
Free Cash Flow Ratio | 6.27 |
Industry Free Cash Flow Ratio | 12.88 |
Sector Free Cash Flow Ratio | 32.90 |
Current Ratio Most Recent Quarter | 4.07 |
Total Cash Per Share | 4.32 |
Book Value Per Share Most Recent Quarter | 3.94 |
Price to Book Ratio | 6.85 |
Industry Price to Book Ratio | 5.95 |
Sector Price to Book Ratio | 22.08 |
Price to Sales Ratio Twelve Trailing Months | 0.00 |
Industry Price to Sales Ratio Twelve Trailing Months | 7.08 |
Sector Price to Sales Ratio Twelve Trailing Months | 6.36 |
Share Statistics |
|
Total Shares Outstanding | 47,976,200 |
Market Capitalization | 1,299,195,496 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | 12/13/2012 |
Last Dividend Amount | 14.00 |
Current Dividend Amount | 5.25 |
Total Years Dividend Increasing | 0 |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | -62.50% |
3-Year Dividend Growth Rate Percentage | -62.50% |
5-Year Dividend Growth Rate Percentage | -62.50% |
All-Time Dividend Growth Rate Percentage | -62.50% |
Dividend Payout Ratio | 0.00% |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | -27.50% |
Reported EPS 12 Trailing Months | -2.83 |
Reported EPS Past Year | 0.71 |
Reported EPS Prior Year | -2.32 |
Net Income Twelve Trailing Months | -15,372,000 |
Net Income Past Year | -97,217,000 |
Net Income Prior Year | -76,246,000 |
Quarterly Revenue Growth YOY | 0.00% |
5-Year Revenue Growth | 0.00% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 207,291,000 |
Total Cash Past Year | 121,136,000 |
Total Cash Prior Year | 201,015,000 |
Net Cash Position Most Recent Quarter | 207,291,000 |
Net Cash Position Past Year | 121,136,000 |
Long Term Debt Past Year | 0 |
Long Term Debt Prior Year | 0 |
Total Debt Most Recent Quarter | 0 |
Equity to Debt Ratio Past Year | 1.00 |
Equity to Debt Ratio Most Recent Quarter | 1.00 |
Total Stockholder Equity Past Year | 137,468,000 |
Total Stockholder Equity Prior Year | 227,539,000 |
Total Stockholder Equity Most Recent Quarter | 188,974,000 |
Free Cash Flow |
|
Free Cash Flow Twelve Trailing Months | -86,306,000 |
Free Cash Flow Per Share Twelve Trailing Months | -1.80 |
Free Cash Flow Past Year | -82,439,000 |
Free Cash Flow Prior Year | -80,226,000 |
Options |
|
Put/Call Ratio | 0.32 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | 1.33 |
MACD Signal | 1.43 |
20-Day Bollinger Lower Band | 8.10 |
20-Day Bollinger Middle Band | 21.50 |
20-Day Bollinger Upper Band | 34.91 |
Beta | -0.63 |
RSI | 58.46 |
50-Day SMA | 21.52 |
150-Day SMA | 27.81 |
200-Day SMA | 33.50 |
System |
|
Modified | 10/4/2024 12:46:21 PM EST |